Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

GlaxoSmithKline And University Of Nottingham Establish Research Center

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/26/2012 | 10:46am CET

Drug maker GlaxoSmithKline PLC (>> GlaxoSmithKline plc) and the University of Nottingham said Thursday that they formalized a collaboration to establish a new laboratory to accommodate the Centre of Excellence for sustainable chemistry and to construct an innovative carbon neutral sustainable chemistry laboratory.

MAIN FACTS:

-The Laboratory for Sustainable Chemistry is being supported by a GBP12 million grant from Glaxo.

-Shares at 0829 GMT, down 10 pence, or 0.71%, at 1,403.5 pence valuing the company at GBP71.28 million.

-By Rory Gallivan, Dow Jones Newswires; 44-20-7842-9411; rory.gallivan@dowjones.com

Stocks mentioned in the article : GlaxoSmithKline plc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE PLC
12/09 FTSE records best week since July, Sky surges 27 percent on Fox bid
12/09DJBayer Teams Up With Versant to Develop Stem-Cell Therapies--Update
12/08 GLAXOSMITHKLINE : Relvar® Ellipta® 100/25 mcg Gains Approval in Japan for Use in..
12/08 GLAXOSMITHKLINE : Bioelectronic Medicine Pioneer, ElectroMedical Technologies, A..
12/07 GLAXOSMITHKLINE : *rpt/ubs cuts glaxosmithkline price target to 1600 pence - 'ne..
12/06 GLAXOSMITHKLINE : *ubs cuts glaxosmithkline price target to 1600 pence - 'neutra..
12/06 ADAPTIMMUNE THERAPEUTICS : Announces Initiation of Myxoid/Round Cell Liposarcoma..
12/05 GLAXOSMITHKLINE : Dominique Limet to step down as CEO of ViiV Healthcare; Debora..
12/05 Astex Joins the Dementia Discovery Fund as a Strategic Investor
12/05 INNOVIVA : Relvar Ellipta 100/25 mcg gains approval in Japan for use in patients..
More news
Sector news : Pharmaceuticals - NEC
12/09 FTSE records best week since July, Sky surges 27 percent on Fox bid
12/09DJASTRAZENECA : FDA Accepts License Application for Durvalumab
12/09DJBayer Teams Up With Versant to Develop Stem-Cell Therapies--Update
12/08 BRISTOL MYERS SQUIBB : Meyers Squibb to pay $19.5 million to settle off-label pr..
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/09 TiGenix Seeks $53 Million IPO For Promising Stem Cell Treatments
12/05 Spark Strengthens Case For Hemophilia Gene Therapy
12/05 GLAXOSMITHKLINE : Robust Pipeline Supports Its 5.5% Dividend Yield
12/02 ALZHEIMER'S DISEASE : Does THC Hold The Key To A Cure?
12/02 5%+ DIVIDEND YIELD PORTFOLIO : Trump And The No Good, Very Bad Month (Nov 2016 R..
Advertisement
Financials ( GBP)
Sales 2016 27 399 M
EBIT 2016 7 209 M
Net income 2016 2 313 M
Debt 2016 13 844 M
Yield 2016 5,49%
P/E ratio 2016 31,41
P/E ratio 2017 18,06
EV / Sales 2016 3,14x
EV / Sales 2017 2,91x
Capitalization 72 071 M
More Financials
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 17,8  GBP
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Andrew Philip Witty Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Birgitte Volck Head-Research & Development
Moncef Slaoui Executive Director & Chairman-Global Vaccines
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC7.65%90 628
JOHNSON & JOHNSON9.29%305 407
ROCHE HOLDING LTD.-17.58%193 824
PFIZER INC.-4.15%192 367
NOVARTIS AG-18.49%182 959
MERCK & CO., INC.15.92%168 820
More Results